First-Episode Psychosis: Antipsychotic Selection and Metabolic Monitoring
A 19-year-old man presents with 6 months of social withdrawal, declining grades, and 3 weeks of auditory hallucinations and the belief that classmates can read his thoughts. He is otherwise healthy, BMI 22, no substance use on screening, and no prior treatment. He is frightened but cooperative, denies suicidal or homicidal ideation, and his parents are supportive and engaged. Baseline labs: fasting glucose 88, A1c 5.2%, lipids normal, prolactin normal, ECG QTc 420 ms. He asks whether he 'has to be on medication forever' and is worried about weight gain.
1. What diagnosis is supported, and what factors should guide your choice of first antipsychotic?
Read the worked answer
Supported diagnosis: schizophrenia (first episode).
Criteria supported by the history:
- ≥6 months of disturbance (6 months of withdrawal/decline plus 3 weeks of active symptoms) with continuous signs.
- Positive symptoms (auditory hallucinations, thought broadcasting) and functional decline (grades).
- No substance-induced or mood explanation evident on screening.
Factors guiding antipsychotic choice in a first episode:
- Efficacy is broadly similar across agents; tolerability and adverse-effect profile drive selection.
- Metabolic risk: he is young with a normal BMI and worried about weight gain - favor an agent with a lower metabolic liability (e.g., aripiprazole or risperidone-class options) over high-risk agents (e.g., olanzapine) unless efficacy demands otherwise.
- Baseline parameters are normal, giving a clean monitoring baseline (glucose, A1c, lipids, prolactin, QTc).
- First-episode patients are highly responsive - use a low starting dose and titrate; they are also more sensitive to extrapyramidal effects.
- Adherence and support: engage the family, discuss depot options for the future, and address his concerns honestly.
2. How do you counsel him about duration of treatment and set up monitoring?
Read the worked answer
Counseling on duration:
- Explain that medication is the cornerstone of preventing relapse; after a first episode with good response, guidelines generally support continued treatment for at least 1-2 years before considering a careful, monitored taper - and longer if risk factors for relapse are present.
- Frame it as 'not necessarily forever, but not something to stop on your own'; abrupt discontinuation markedly increases relapse risk.
- Address the weight concern directly: choose a lower-metabolic-risk agent, and pair medication with diet/activity counseling and regular weight checks.
Monitoring plan:
- Metabolic: weight/BMI and waist at baseline and frequently early on, then periodically; fasting glucose/A1c and lipids at baseline, ~12 weeks, and then at least annually (more often if changes).
- Cardiac: follow-up ECG if QTc borderline or other QT-prolonging agents are added.
- Movement: screen for extrapyramidal symptoms and akathisia at each visit.
- Prolactin if symptoms suggest elevation.
- Adherence and response: reassess symptoms and function regularly; involve family; provide psychoeducation and psychosocial supports (e.g., supported education/employment).
Exam-tested judgment: Match the drug to the patient's risk profile, use low first-episode dosing, and build structured metabolic/movement monitoring into the plan from day one.